Degenhardt Tom, Wuerstlein Rachel, Eggersmann Tanja, Harbeck Nadia
a Breast Center, Department of Obstetrics and Gynecology , University Hospital, Ludwig-Maximilian-University Munich (LMU) , Munich , Germany.
Expert Opin Drug Saf. 2018 Mar;17(3):325-330. doi: 10.1080/14740338.2018.1429402. Epub 2018 Jan 28.
Despite improvements in the diagnosis and management of early stage breast cancer, about one third of the patients still progress to metastatic disease. Most of the patients with metastatic breast cancer have a hormone receptor positive and human epidermal growth factor receptor 2 negative subtype with a median survival of more than 3 years. For these patients, endocrine therapy with its favorable toxicity profile is the current standard of care. However, patients with metastatic breast cancer have an incurable disease. Therefore, not only efficacy but also quality of life are key when selecting a therapy regimen. Areas covered: This paper aims to discuss the efficacy and toxicity profile of the new endocrine-based therapy option palbociclib together with endocrine treatment. Expert opinion: The addition of targeted agents like palbociclib can overcome intrinsic or acquired resistance to endocrine therapy and substantially prolong progression free survival. The combination of palbociclib plus endocrine therapy is associated with a tolerable and well manageable toxicity profile as well as maintenance of quality of life. Thus, addition of palbociclib to endocrine therapy offers a new and important treatment option for hormone receptor positive metastatic breast cancer.
尽管早期乳腺癌的诊断和治疗有所改善，但仍约有三分之一的患者会进展为转移性疾病。大多数转移性乳腺癌患者为激素受体阳性且人表皮生长因子受体2阴性亚型，中位生存期超过3年。对于这些患者，具有良好毒性特征的内分泌治疗是当前的标准治疗方法。然而，转移性乳腺癌患者的疾病无法治愈。因此，在选择治疗方案时，疗效和生活质量都是关键。涵盖领域：本文旨在探讨新的基于内分泌的治疗药物哌柏西利与内分泌治疗联合应用的疗效和毒性特征。专家观点：添加哌柏西利等靶向药物可克服对内分泌治疗的内在或获得性耐药，并显著延长无进展生存期。哌柏西利联合内分泌治疗具有可耐受且易于管理的毒性特征，同时能维持生活质量。因此，在内分泌治疗中添加哌柏西利为激素受体阳性转移性乳腺癌提供了一种新的重要治疗选择。
